212 related articles for article (PubMed ID: 21897074)
1. [Conditioning regimen of allogeneic hematopoietic stem cell transplantation for aplastic anemia in Japan].
Mori T
Rinsho Ketsueki; 2011 Aug; 52(8):674-8. PubMed ID: 21897074
[No Abstract] [Full Text] [Related]
2. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
[TBL] [Abstract][Full Text] [Related]
3. The Outcome of Unrelated Hematopoietic Stem Cell Transplants with Total Body Irradiation (800 cGy) and Cyclophosphamide (120 mg/kg) in Adult Patients with Acquired Severe Aplastic Anemia.
Lee JW; Cho BS; Lee SE; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Min WS; Park CW
Biol Blood Marrow Transplant; 2011 Jan; 17(1):101-8. PubMed ID: 20601037
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up of allogeneic stem cell transplantation in patients with severe aplastic anemia after conditioning with cyclophosphamide plus antithymocyte globulin.
Kröger N; Zabelina T; Renges H; Krüger W; Kordes U; Rischewski J; Schrum J; Horstmann M; Ayuk F; Erttmann R; Kabisch H; Zander AR
Ann Hematol; 2002 Nov; 81(11):627-31. PubMed ID: 12454700
[TBL] [Abstract][Full Text] [Related]
5. Fludarabine, cyclophosphamide, anti-thymocyteglobulin, and low-dose total body irradiation conditioning enables 1-HLA-locus-mismatched hematopoietic stem cell transplantation for very severe aplastic anemia without affecting ovarian function.
Okuda S; Terasako K; Oshima K; Sato M; Nakasone H; Kako S; Yamazaki R; Tanaka Y; Tanihara A; Higuchi T; Nishida J; Kanda Y
Am J Hematol; 2009 Mar; 84(3):167-9. PubMed ID: 19195036
[TBL] [Abstract][Full Text] [Related]
6. A randomized comparison of cyclophosphamide vs. reduced dose cyclophosphamide plus fludarabine for allogeneic hematopoietic cell transplantation in patients with aplastic anemia and hypoplastic myelodysplastic syndrome.
Kim H; Lee JH; Joo YD; Bae SH; Hyun MS; Lee JH; Kim DY; Lee WS; Ryoo HM; Kim MK; Park JH; Lee KH;
Ann Hematol; 2012 Sep; 91(9):1459-69. PubMed ID: 22526363
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic hematopoietic cell transplantation without total body irradiation from unrelated donor in adult patients with idiopathic aplastic anemia: fludarabine versus cyclophosphamide-ATG.
Kim H; Lee KH; Kim I; Sohn SK; Jung CW; Joo YD; Kim SH; Kim BS; Choi JH; Kwak JY; Kim MK; Bae SH; Shin HJ; Won JH; Lee WS; Oh S; Kim HJ; Park JH;
Leuk Res; 2014 Jul; 38(7):730-6. PubMed ID: 24840870
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcome after bone marrow transplantation for aplastic anemia using cyclophosphamide and total lymphoid irradiation as conditioning regimen.
Inamoto Y; Suzuki R; Kuwatsuka Y; Yasuda T; Takahashi T; Tsujimura A; Sugimoto K; Oba T; Terakura S; Atsuta Y; Murata M; Ito M; Kodera Y; Miyamura K
Biol Blood Marrow Transplant; 2008 Jan; 14(1):43-9. PubMed ID: 18158960
[TBL] [Abstract][Full Text] [Related]
9. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic hematopoietic stem cell transplantation for patients with severe aplastic anemia following nonmyeloablative conditioning using 200-cGy total body irradiation and fludarabine.
Koh LP; Koh MB; Ng HY; Hwang WY; Goh YT; Linn YC; Ng HJ; Chuah CT; Tan KW; Loh YS; Tan DC; Tan PH; Tan PH
Biol Blood Marrow Transplant; 2006 Aug; 12(8):887-90. PubMed ID: 16864060
[No Abstract] [Full Text] [Related]
11. Fludarabine-based conditioning chemotherapy for allogeneic hematopoietic stem cell transplantation in acquired severe aplastic anemia.
Al-Zahrani H; Nassar A; Al-Mohareb F; Al-Sharif F; Mohamed S; Al-Anazi K; Patel M; Rasheed W; Saleh AJ; Bakr M; Ahmed S; Ibrahim K; Hussain F; Elkum N; Elhassan T; Nurgat Z; Chaudhri N; Aljurf M
Biol Blood Marrow Transplant; 2011 May; 17(5):717-22. PubMed ID: 20736079
[TBL] [Abstract][Full Text] [Related]
12. Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party.
Bacigalupo A; Locatelli F; Lanino E; Marsh J; Socié G; Maury S; Prete A; Locasciulli A; Cesaro S; Passweg J;
Bone Marrow Transplant; 2005 Dec; 36(11):947-50. PubMed ID: 16205733
[TBL] [Abstract][Full Text] [Related]
13. The gut mucosa barrier is preserved during allogeneic, haemopoietic stem cell transplantation with reduced intensity conditioning.
Johansson JE; Brune M; Ekman T
Bone Marrow Transplant; 2001 Oct; 28(8):737-42. PubMed ID: 11781624
[TBL] [Abstract][Full Text] [Related]
14. [Second transplantation for graft failure after allogeneic hematopoietic stem cell transplantation--a retrospective survey by Kanto Study Group for Cell Therapy].
Hagihara M; Kanamori H; Sakai M; Mori T; Nakaseko C; Aotsuka N; Uehara T; Sakura T; Yoshiba F; Kawai N; Tanaka M; Fujisawa S; Ohwada C; Wakita H; Yokota A; Kawamura T; Maruta A; Sakamaki H; Okamoto S;
Rinsho Ketsueki; 2010 Jun; 51(6):390-7. PubMed ID: 20622484
[TBL] [Abstract][Full Text] [Related]
15. Addition of low-dose busulfan to cyclophosphamide in aplastic anemia patients prior to allogeneic bone marrow transplantation to reduce rejection.
Dulley FL; Vigorito AC; Aranha FJ; Sturaro D; Ruiz MA; Saboya R; Macedo MC; Da Silva RL; Chamone DA; Mehta J; Bacigalupo A; De Souza CA
Bone Marrow Transplant; 2004 Jan; 33(1):9-13. PubMed ID: 14578930
[TBL] [Abstract][Full Text] [Related]
16. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2.
Chae YS; Sohn SK; Kim JG; Cho YY; Moon JH; Shin HJ; Chung JS; Cho GJ; Yang DH; Lee JJ; Kim YK; Kim HJ
Bone Marrow Transplant; 2007 Sep; 40(6):541-7. PubMed ID: 17637692
[TBL] [Abstract][Full Text] [Related]
17. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
[TBL] [Abstract][Full Text] [Related]
18. Allografting in patients with severe, refractory aplastic anemia using peripheral blood stem cells and a fludarabine-based conditioning regimen: the Mexican experience.
Gómez-Almaguer D; Vela-Ojeda J; Jaime-Pérez JC; Gutiérrez-Aguirre CH; Cantú-Rodríguez OG; Sobrevilla-Calvo P; Rivas-Vera S; Gómez-Rangel JD; Ruiz-Argüelles GJ
Am J Hematol; 2006 Mar; 81(3):157-61. PubMed ID: 16493614
[TBL] [Abstract][Full Text] [Related]
19. Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients.
Kröger N; Zabelina T; Krüger W; Renges H; Stute N; Kabisch H; Jaburg N; Löliger C; Krüll A; Zander AR
Bone Marrow Transplant; 2001 Feb; 27(4):349-54. PubMed ID: 11313663
[TBL] [Abstract][Full Text] [Related]
20. [A modified myeloablative conditioning regimen for allogeneic hematopoietic stem cell transplantation, consisting of intravenous busulfan, cyclophosphamide and total lymphoid irradiation, in advanced leukemia].
Nakamae H; Terada Y; Nakane T; Koh H; Nakamae M; Aimoto R; Hirose A; Hayashi Y; Nishimoto M; Inoue E; Yoshimura T; Inoue A; Koh KR; Yamane T; Hino M
Gan To Kagaku Ryoho; 2010 Sep; 37(9):1691-5. PubMed ID: 20841930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
